Articles On Neuren Pharmaceuticals (ASX:NEU)

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

Over the past month, a number of US FDA approvals have moved the share prices of global pharma stocks, including those traded here on the ASX. The biggest FDA announcement during the month came out of US-based Biogen, which received a contr...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It has been...

Highlights: Clear and constructive guidance received from pre-IND meetings with the FDA Office of Neuroscience for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman and Pitt Hopkins syndromes Positive outcome is an import...

The USA is the world’s largest healthcare market and therefore a dream for ASX health stocks to enter. This is no easy feat – needing to obtain the approval from the FDA, a regulator renowned as the world’s most sophisticated – but one that...

Neuren Pharmaceuticals (ASX:NEU) says it has received "clear and constructive guidance" from the US FDA Office of Neuroscience in pre-IND meetings for Phase 2 clinical trials of NNZ-2591.

Summary Neuren Pharmaceuticals obtained a Canadian patent grant for trofinetide, with a patent term that extends to January 2032. Health technology company Medibio Limited has secured a pre-submission meeting with the FDA for a new 510...

Neuren Pharmaceuticals (ASX:NEU) has announced that manufacturing of the drug substance for phase two trials of NNZ-2591 has been successfully completed on schedule.

Source:Master Video, Shutterstock Summary Neuren Pharmaceuticals updated the market that drug manufacturing for Phase 2 trials of NNZ-2591 has been completed. Cann Global’s Canntab Therapeutics has obtained an Australian patent with e...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are trending higher in early afternoon trade. This comes after the biotech company announced it has successfully completed manufacturing a drug substance for its Phase 2 trials. At the time of w...

What sounds more appealing for investors: a billion-dollar blockbuster drug with mass market appeal, or an ‘orphan’ drug targeting a ... Read More The post Dr Boreham’s Crucible: Is Neuren Pharmaceuticals’ Rett bet set for collect? appeared...

Australian biotechnology company Neuren Pharmaceuticals (ASX:NEU) has reported a phase one trial of its twice-daily oral investigative therapy NNZ-2591 found it was safe and well-tolerated for seven days.

Invex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use a diabetic drug for a neurological condition in desperate need for treatment. The biopharmaceutical company is focused on repurposing the d...

The company is developing new therapies to treat serious neurological disorders that emerge in early childhood, none of which have any approved medicines, and is advancing development of its second drug candidate NNZ-2591 for Phelan-McDermi...

Small caps had the Monday blues, with their worst intra-day result in two weeks. The Small Ordinaries index of 200 small-cap companies on Monday finished down 49.2 points, or 1.57 per cent, to 3,084.4. It was the Small Ords’ worst single-da...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price has changed direction today despite positive news on its drug trials.  In early morning trade, the biopharma company’s shares were up 2.7% to $1.50. But the Neuren share price has since...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Melbourne-based company Neuren Pharmaceuticals (ASX:NEU) says it has initiated the manufacture of NNZ-2591 to supply the planned phase two clinical trials.

The sudden drop in spot gold prices and reintroduction of COVID-19 restrictions in New Zealand have hit the relevant ASX small caps this morning. After 100 days of being virus-free, four COVID-19 cases were detected in the country. New Zeal...

ASX companies continued to raise money in July, with over $4bn shelled out by investors, taking 2020’s total above $30bn. According to Bloomberg, there has been $32.3bn worth of cash raised between January 1 and August 3. This is well ahead...

Cancer therapeutics biotech Immutep (ASX:IMM) has enrolled and dosed the last patient for a segment of its phase 2 study into cancer treatments. The recruitment and dosing milestone was for stage 2 of Part A of its TACTI-002 phase II study....

Biotechnology outfit Neuren Pharmaceuticals was fronting funds on Thursday morning.

Fortunes were to be made in ASX health stocks during March and April as investors looked for salvation from the COVID-19 pandemic fears rocking markets. However, once the two biggest health stocks Resmed (ASX:RMD) and CSL (ASX:CSL) are take...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Markets be...

27 May 2020 - Neuren Pharmaceuticals (ASX:NEU) today announced the appointment of Jon Pilcher and Patrick Davies as Chief Executive Officer and non-executive Chair respectively.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Cochlear’s...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   This week’s big themes The ca...

While we need all the bacteria fighters we can get right now, they are not immune to the coronovirus panic and Next Science (ASX:NXS) is the latest to admit it hasn’t been able to escape the impact. The company, which listed last April and...

Neuren Pharmaceuticals (ASX: NEU) is getting interesting results from a mouse trial of a treatment for Phelan-McDermid syndrome (PMS), a rare genetic illness which exhibits symptoms of conditions including autism and epilepsy. The study fou...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price has dropped lower with the market on Friday despite the release of a positive update. In morning trade the pharmaceutical company’s shares are down 3.5% to $1.98. What did Neuren Pharm...

Trofinetide is an investigational drug developed by Neuren designed to treat the core symptoms of Rett syndrome by potentially reducing neuroinflammation and supporting synaptic function.

04 Mar 2020 - Acadia Pharmaceuticals Inc. and Neuren Pharmaceuticals (ASX:NEU) announced today that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) d…

Neuren Pharmaceuticals (ASX:NEU) has been granted Rare Pediatric Disease (RPD) designation for its Rett syndrome treatment, a serious and rare neurological disorder mainly affecting little girls. The US Food and Drug Administration (FDA) gr...

Drug development is an extensive process and includes drug discovery & development, pre-clinical and clinical research and FDA approvals, including Post-Market Drug Safety Monitoring. The first and the most essential step of drug devel...

Australian health care sector is booming with strong growth prospects amid global trade worries and market volatility. Being dynamic and lucrative sector, it catches investors’ attention often. When the share price of a company is multiplie...

It can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve small cap. But there are as many moments when CEOs, managing directors, and executive chairmen and women earn their keep. We uncovered the top 1...

Australia’s health care industry is one of the fastest growing industries in the country that is making substantial progress driven by new technological advancements. The country’s government is injecting billions of dollars into modernisin...

Drug Development Process The drug development process starts from drug discovery and ends at the launch of the new pharmaceutical product in the market. The process includes drug discovery and development, preclinical trials, clinical trial...

One of the oldest tropes in journalism is the miracle cure. Startup Daily is old enough to remember when Filipino faith healers were all the rage in the 1980s – think Penn & Teller meets House. More recently, there was US blood-testing...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Health care system of Australia is considered as one of the best, globally, as it delivers safe and affordable health care solutions and services to the citizens. Health care sector in Australia comprises of medical service, medical insuran...

Health stocks are reckoned amid those that can rapidly grow from a single line of product with small market capitalisation to a company worth over billions. Regarded as one of the most exciting sectors of the stock market, health stocks hol...

Australian health care sector is growing potentially by generating significant profits in a short period, and that is something the investors are also closely monitoring. Australia’s public healthcare system is one of the world’s best, join...

Strong gains among selected life science shares is fuelling optimism the sector may have further to run. Life sciences stocks are involved in things like biotech, genetics, pharmaceuticals and medical devices. In a low growth earnings envir...

A drug developed by Neuren Pharmaceuticals (ASX: NEU) to treat debilitating childhood neurodevelopmental disorders has been granted an orphan drug designation by the US Food and Drug Administration. Drug candidate NNZ-2591 has previously de...

The Federal agency of the United States Department of Health and Human Services, US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren Pharmaceuticals’ (ASX: NEU) NNZ-2591. Neuren’s NNZ-2591 drug is used in th...

Agri-tech business Roots Sustainable Agricultural Technologies (ASX:ROO) says its crop-cooling technology continues to gain traction with commercial cannabis producers. The Israeli-based company released results from the operation of its Ro...